Yooyoung launches new combination form to treat dyslipidemias

Published: 2012-10-11 06:57:00

Updated: 2012-10-11 06:57:00

Yooyoung Pharmaceutical said yesterday it has recently launched Pravafenix, SMB’s fixed dose combination drug to treat dyslipidemias, with an exclusive marketing right here.

Approved by the European Commission in April 2011, Pravafenix is a medicine that contains the active substances containi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK